These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29190880)

  • 1. Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism.
    Fumarola C; Cretella D; La Monica S; Bonelli MA; Alfieri R; Caffarra C; Quaini F; Madeddu D; Falco A; Cavazzoni A; Digiacomo G; Mazzaschi G; Vivo V; Barocelli E; Tiseo M; Petronini PG; Ardizzoni A
    Oncotarget; 2017 Nov; 8(54):91841-91859. PubMed ID: 29190880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines.
    Fumarola C; Bozza N; Castelli R; Ferlenghi F; Marseglia G; Lodola A; Bonelli M; La Monica S; Cretella D; Alfieri R; Minari R; Galetti M; Tiseo M; Ardizzoni A; Mor M; Petronini PG
    Front Oncol; 2019; 9():179. PubMed ID: 30972293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
    Katoh M
    Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung.
    Usul Afsar C; Sahin B; Gunaldi M; Kılıc Bagir E; Gumurdulu D; Burgut R; Erkisi M; Kara IO; Paydas S; Karaca F; Ercolak V
    Int J Clin Exp Pathol; 2015; 8(9):9760-71. PubMed ID: 26617686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells.
    Chi F; Griffiths JI; Nath A; Bild AH
    Breast Cancer Res; 2024 Mar; 26(1):54. PubMed ID: 38553760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR Inhibitor Ameliorates Hypophosphatemia and Impaired Engrailed-1/Wnt Signaling in FGF2 High Molecular Weight Isoform Transgenic Mice.
    Du E; Xiao L; Hurley MM
    J Cell Biochem; 2016 Sep; 117(9):1991-2000. PubMed ID: 26762209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer.
    Elakad O; Häupl B; Labitzky V; Yao S; Küffer S; von Hammerstein-Equord A; Danner BC; Jücker M; Urlaub H; Lange T; Ströbel P; Oellerich T; Bohnenberger H
    NPJ Precis Oncol; 2022 Jul; 6(1):52. PubMed ID: 35853934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.
    Golfmann K; Meder L; Koker M; Volz C; Borchmann S; Tharun L; Dietlein F; Malchers F; Florin A; Büttner R; Rosen N; Rodrik-Outmezguine V; Hallek M; Ullrich RT
    Oncogene; 2018 Oct; 37(42):5682-5693. PubMed ID: 29970903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.
    Lefèvre G; Babchia N; Calipel A; Mouriaux F; Faussat AM; Mrzyk S; Mascarelli F
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1047-57. PubMed ID: 19029025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Fibroblast Growth Factor Receptor (FGFR) with BGJ398 in a Gastric Cancer Model.
    Schmidt K; Moser C; Hellerbrand C; Zieker D; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    Anticancer Res; 2015 Dec; 35(12):6655-65. PubMed ID: 26637881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma.
    Chudasama P; Renner M; Straub M; Mughal SS; Hutter B; Kosaloglu Z; Schweßinger R; Scheffler M; Alldinger I; Schimmack S; Persigehl T; Kobe C; Jäger D; von Kalle C; Schirmacher P; Beckhaus MK; Wolf S; Heining C; Gröschel S; Wolf J; Brors B; Weichert W; Glimm H; Scholl C; Mechtersheimer G; Specht K; Fröhling S
    Clin Cancer Res; 2017 Feb; 23(4):962-973. PubMed ID: 27535980
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study.
    Addeo A; Rothschild SI; Holer L; Schneider M; Waibel C; Haefliger S; Mark M; Fernandez E; Mach N; Mauti L; Jermann PM; Alborelli I; Calgua B; Savic-Prince S; Joerger M; Früh M
    Lung Cancer; 2022 Oct; 172():154-159. PubMed ID: 36099710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer.
    Cai W; Song B; Ai H
    Am J Transl Res; 2019; 11(3):1616-1625. PubMed ID: 30972187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer.
    Malchers F; Dietlein F; Schöttle J; Lu X; Nogova L; Albus K; Fernandez-Cuesta L; Heuckmann JM; Gautschi O; Diebold J; Plenker D; Gardizi M; Scheffler M; Bos M; Seidel D; Leenders F; Richters A; Peifer M; Florin A; Mainkar PS; Karre N; Chandrasekhar S; George J; Silling S; Rauh D; Zander T; Ullrich RT; Reinhardt HC; Ringeisen F; Büttner R; Heukamp LC; Wolf J; Thomas RK
    Cancer Discov; 2014 Feb; 4(2):246-57. PubMed ID: 24302556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.